Jessica L. Porter

Jessica L. Porter

Auto-generated profile, based on publicly available information

Jessica L. Porter

Department of Microbiology and Immunology at the Doherty Institute University of Melbourne Melbourne VIC 3000 Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
APAcha Pidot
Acha Pidot
MHMarion Herisse
Marion Herisse
LSLiam Sharkey
Liam Sharkey
LALiselle Atkin
Liselle Atkin
JPJessica L. Porter
Jessica L. Porter
TSTimothy Stinear
Timothy Stinear
The nargenicin family of antibiotics are macrolides containing a rare ether‐bridged cis‐decalin motif. Several of these compounds are highly active against multi‐drug resistant organisms. Despite the identification of the first members of this family almost 40 years ago, the genetic basis for the production of these molecules and the enzyme responsible for formation of the oxa bridge, remain unknown. Here, the 85 kb nargenicin biosynthetic gene cluster was identified from a human pathogenic Nocardia arthritidis isolate and this locus is solely responsible for nargenicin production. Further investigation of this locus revealed a putative iron‐α‐ketoglutarate‐dependent dioxygenase, which was found to be responsible for the formation of the ether bridge from the newly identified deoxygenated precursor, 8,13‐deoxynargenicin. Uncovering the nargenicin biosynthetic locus provides a molecular basis for the rational bioengineering of these interesting antibiotic macrolides.

6 November 2015 in Microbial Genomics
Verified
Journal Article
Open access
EMElla Meumann
Ella Meumann
MGMaria Globan
Maria Globan
JFJanet A. M. Fyfe
Janet A. M. Fyfe
DLDavid Leslie
David Leslie
JPJessica L. Porter
Jessica L. Porter
TSTimothy Stinear
Timothy Stinear
We report a case of chronic pulmonary multi-drug-resistant tuberculosis. Despite 14 years of treatment, Mycobacterium tuberculosis was persistently isolated from sputum. Following treatment cessation the patient remained well, although M. tuberculosis was isolated from sputum for a further 8 years. Genome sequencing of eight serial M. tuberculosis isolates cultured between 1991 and 2011 revealed 17 mutations (0.8 mutations per genome year− 1). Eight of these were persisting mutations and only two mutations were detected in the 7 years following cessation of treatment in 2004. In four isolates there were mixed alleles, suggesting the likely presence of bacterial subpopulations. The initial 1991 isolate demonstrated genotypic resistance to isoniazid (katG W91R), rifampicin (rpoB S531L), ethambutol (embB M306V), streptomycin (gidB L16R), quinolones (gyrA S95T) and P-aminosalicylic acid (thyA T202A). Subsequent resistance mutations developed for pyrazinamide (pncA I31F) and ethionamide (ethA frameshift). Such information might have been instructive when developing a treatment regimen. In retrospect and with the benefit of high-resolution genomic hindsight we were able to determine that the patient received only one or two active anti-tuberculous agents for most of their treatment. Additionally, mutations in bacA and Rv2326c were detected, which may have contributed to the persistent but mild disease course. BacA is likely to be associated with maintenance of chronic infection and Rv2326c with a decreased bacterial metabolic state. These results expand our understanding of M. tuberculosis evolution during human infection and underline the link between antibiotic resistance and clinical persistence.

30 November 2015 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MEMiriam Eddyani
Miriam Eddyani
KVKoen Vandelannoote
Koen Vandelannoote
CMConor J Meehan
Conor J Meehan
SBSabin Bhuju
Sabin Bhuju
JPJessica L Porter
Jessica L Porter
BJBouke C de Jong
Bouke C de Jong
Increased availability of Next Generation Sequencing (NGS) techniques allows, for the first time, to distinguish relapses from reinfections in patients with multiple Buruli ulcer (BU) episodes. We compared the number and location of single nucleotide polymorphisms (SNPs) identified by genomic screening between four pairs of Mycobacterium ulcerans isolates collected at the time of first diagnosis and at recurrence, derived from a collection of almost 5000 well characterized clinical samples from one BU treatment center in Benin. The findings suggest that after surgical treatment—without antibiotics—the second episodes were due to relapse rather than reinfection. Since specific antibiotics were introduced for the treatment of BU, the one patient with a culture available from both disease episodes had M. ulcerans isolates with a genomic distance of 20 SNPs, suggesting the patient was most likely reinfected rather than having a relapse. To our knowledge, this study is the first to study recurrences in M. ulcerans using NGS, and to identify exogenous reinfection as causing a recurrence of BU. The occurrence of reinfection highlights the contribution of ongoing exposure to M. ulcerans to disease recurrence, and has implications for vaccine development. We compared the whole genomes of four pairs of Mycobacterium ulcerans isolates collected at the time of first diagnosis and at recurrence, derived from a collection of almost 5000 well characterized clinical samples from one BU treatment center in Benin. Our findings suggest that after surgical treatment—without antibiotics—the second episodes were due to relapse rather than reinfection. Since specific antibiotics were introduced for the treatment of BU, the one patient with a culture available from both disease episodes had M. ulcerans isolates with a larger genomic distance, suggesting that the patient was most likely reinfected rather than having a relapse. To our knowledge, this study is the first to assess recurrences in M. ulcerans using whole genomes, and to identify exogenous reinfection as causing a recurrence of BU. The occurrence of reinfection highlights the contribution of ongoing exposure to M. ulcerans to disease recurrence, and has implications for vaccine development.

3 May 2024 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SMStephen Muhi
Stephen Muhi
ABAndrew H Buultjens
Andrew H Buultjens
JPJessica L Porter
Jessica L Porter
JMJulia L Marshall
Julia L Marshall
MDMarcel Doerflinger
Marcel Doerflinger
TSTimothy Stinear
Timothy Stinear
Critical scientific questions remain regarding infection with Mycobacterium ulcerans, the organism responsible for the neglected tropical disease, Buruli ulcer (BU). A controlled human infection model has the potential to accelerate our knowledge of the immunological correlates of disease, to test prophylactic interventions and novel therapeutics. Here we present microbiological evidence supporting M. ulcerans JKD8049 as a suitable human challenge strain. This non-genetically modified Australian isolate is susceptible to clinically relevant antibiotics, can be cultured in animal-free and surfactant-free media, can be enumerated for precise dosing, and has stable viability following cryopreservation. Infectious challenge of humans with JKD8049 is anticipated to imitate natural infection, as M. ulcerans JKD8049 is genetically stable following in vitro passage and produces the key virulence factor, mycolactone. Also reported are considerations for the manufacture, storage, and administration of M. ulcerans JKD8049 for controlled human infection.

24 January 2019 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
APAcha Pidot
Acha Pidot
MHMarion Herisse
Marion Herisse
LSLiam Sharkey
Liam Sharkey
LALiselle Atkin
Liselle Atkin
JPJessica L. Porter
Jessica L. Porter
TSTimothy Stinear
Timothy Stinear
The nargenicin family of antibiotics are macrolides containing a rare ether‐bridged cis‐decalin motif. Several of these compounds are highly active against multi‐drug resistant organisms. Despite the identification of the first members of this family almost 40 years ago, the genetic basis for the production of these molecules and the enzyme responsible for formation of the oxa bridge, remain unknown. Here, the 85 kb nargenicin biosynthetic gene cluster was identified from a human pathogenic Nocardia arthritidis isolate and this locus is solely responsible for nargenicin production. Further investigation of this locus revealed a putative iron‐α‐ketoglutarate‐dependent dioxygenase, which was found to be responsible for the formation of the ether bridge from the newly identified deoxygenated precursor, 8,13‐deoxynargenicin. Uncovering the nargenicin biosynthetic locus provides a molecular basis for the rational bioengineering of these interesting antibiotic macrolides.

23 December 2025 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
ABAndrew H. Buultjens
Andrew H. Buultjens
KVKoen Vandelannoote
Koen Vandelannoote
JPJessica L. Porter
Jessica L. Porter
SMStephen Muhi
Stephen Muhi
EHEmma C. Hobbs
Emma C. Hobbs
TSTimothy Stinear
Timothy Stinear
Buruli ulcer in southeastern Australia is a zoonosis caused by infection with Mycobacterium ulcerans . Australian native possums are a major wildlife reservoir, and infected possums shed M. ulcerans in their excreta, with mosquitoes being the major transmitting vector in this region. Buruli ulcer is geographically restricted, and this feature, combined with an average 4.8-month incubation period, makes tracking M. ulcerans environmental spread and timely identification of new Buruli ulcer endemic areas challenging. While human mobility complicates transmission tracing, we used the highly territorial behavior of native possums and high-resolution pathogen genomics to confidently identify new Buruli ulcer endemic areas in Melbourne’s inner northwest and southern suburbs of Geelong. Using pathogen genomic phylodynamic modeling, we estimated that M. ulcerans was introduced to these areas 2–6 years before the emergence of human Buruli ulcer cases. This study shows how possum excreta surveys combined with pathogen genome data can pinpoint new Buruli ulcer endemic areas, thus providing critical local knowledge for targeted public health interventions to reduce exposure risk and ensure early diagnosis. IMPORTANCE: Buruli ulcer is a debilitating skin disease caused by Mycobacterium ulcerans , with transmission in southeastern Australia involving native possums as wildlife reservoirs and mosquitoes as vectors. Early detection of new endemic areas is critical to preventing human disease, yet is hindered by the pathogen’s long incubation period, highly focal transmission, and the mobility of human hosts. This study demonstrates how structured possum excreta surveys, combined with high-resolution pathogen genomics, can confidently identify new Buruli ulcer endemic areas in southeastern Australia. By confirming local transmission in Melbourne’s inner northwest and Geelong through genome matching between possum- and human-derived M. ulcerans , we provide a framework for targeted, timely public health interventions. This integrated wildlife-environment-human approach exemplifies the power of One Health surveillance to detect and manage emerging zoonotic threats, offering a scalable model for other regions where Buruli ulcer is endemic.